Active, not recruitingPhase 2NCT05996523

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer

Studying Squamous cell carcinoma of the oropharynx

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Charalampos Floudas, M.D., M.D
National Cancer Institute (NCI)
Intervention
PRGN-2009(biological)
Enrollment
16 target
Eligibility
18-120 years · All sexes
Timeline
20232030

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05996523 on ClinicalTrials.gov

Other trials for Squamous cell carcinoma of the oropharynx

Additional recruiting or active studies for the same condition.

See all trials for Squamous cell carcinoma of the oropharynx

← Back to all trials